AstraZeneca is set to conduct a global clinical trial of Calquence (acalabrutinib) to treat cytokine storm that manifests in severely ill Covid-19 patients.
Named CALAVI, the trial will compare the safety and efficacy of the drug plus best supportive care (BSC) to BSC alone in patients hospitalised due to Covid-19-related respiratory complications.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
